SynVax, Inc. is a biopharmaceutical company with a mission to successfully discover, develop, and commercialize pharmaceutical products for use in infection, pain, and cardiology. At least five significant discoveries are currently ready for development, and more are in the pipeline. Animal studies have been done on three products. The products are based on advanced peptide structure-function analyses and expertise in peptide synthesis. Patent has been issued on one product and pending on another. The pharmaceutical markets the company will address are currently in excess of $10 billion in annual sales
